Abstract Allergy diagnosis is based on the patient's clinical history and can be strengthened by tests that confirm the origin of sensitization. In the past 25 years, these tests have evolved from the exclusive in vivo or in vitro use of allergen extracts, to complementary molecular-based diagnostics that rely on in vitro measurements of IgE reactivity to individual allergens. For this to occur, an increase in our understanding of the molecular structure of allergens, largely due to the development of technologies such as molecular cloning and expression of recombinant allergens, X-ray crystallography, or nuclear magnetic resonance (NMR), has been essential. New in vitro microarray or multiplex systems are now available to measure IgE against a selected panel of purified natural or recombinant allergens. The determination of the threedimensional structure of allergens has facilitated detailed molecular studies, including the analysis of antigenic determinants for diagnostic purposes.
present in a specific area. For this, knowledge of the structural features shared by homologous allergens and of molecular structures of antigenic determinants is essential. In addition, the stability of the allergens used for molecular diagnosis may be improved by avoiding degradation by proteolytic enzymes, often present in extracts. Molecular diagnosis, used within the context of the patient's clinical history, is an effective approach to identify patient's IgE sensitization profiles, which can be highly heterogeneous or show geographical variability [7, 8••] . Molecular diagnosis has proven beneficial and able to improve allergy diagnosis based solely on allergen extracts [7, 8••, 9-11] . In this review, recent progress on defining molecular features of allergens that are relevant for allergy diagnosis will be evaluated.
Update of Allergen Nomenclature and Recently Identified Allergens
The identification of new allergens, name assignment, and assessment of their allergenic relevance is necessary for the selection of panels of allergens for molecular diagnosis. The Allergen Nomenclature Sub-committee from the World Health Organization and International Union of Immunological Societies (WHO/IUIS) maintains a systematic nomenclature of allergenic proteins and publishes the official database of approved allergen names (www.allergen.org). The Subcommittee recently revised the current nomenclature to reflect progress in identification, cloning, and sequencing of allergens, while increasing consistency in the classification of allergens. Names were updated for respiratory allergens from birch and ragweed pollen, midge larvae, and horse dander; food allergens from peanut, cow's milk, and tomato; and cereal grain allergens [12] .
In the last years, new allergens were identified that may contribute to improved allergy diagnosis, including panels of inhaled allergens (i.e., olive pollen) and food allergens (i.e., kiwi) [13, 14] . New allergens originating from domestic animals, such as small mammals and rodents which have become popular pets in the USA and Europe, have been reported. These include Fel d 1-like allergens from dogs and rabbits [15, 16] , a major dog allergen Can f 5 which is a prostatic kallikrein [17] , and two guinea pig lipocalins, Cav p 2 and Cav p 3. The latter are major allergens, proven to be valuable for diagnosis of guinea pig allergy when combined with serum albumin Cav p 4 [18] . Several new allergens, classified in up to 33 groups, have been identified in mite. They include two major allergens: Der p 23, a peritrophin-like protein, and Der f 24, an ubiquinolcytochrome c reductase-binding protein homolog [19•, 20] . Both allergens show high prevalence of IgE sensitization, comparable with the one reported for Der p 1 (93 %) and Der p 2 (77 %), currently used to diagnose mite-allergic patients [21] . The need to add new allergens for improving diagnosis of mite allergy will need to be evaluated, and may not be as critical as it is for other allergen sources, such as kiwi fruit and honeybee venom. The use of larger allergen panels can improve the diagnostic sensitivity in some cases and has revealed the importance of allergens underrepresented in commercial therapeutic extracts [8••, 22 ••].
Three-Dimensional Structures of Allergens
The WHO/IUIS official database of systematic allergen nomenclature (www.allergen.org) currently contains over 780 allergens. In the past 15 years, the threedimensional structures of just over 100 allergens have been determined thanks to the development of X-ray crystallography and nuclear magnetic resonance technologies (Tables 1 and 2 ). The availability of recombinant allergens has also contributed to the determination of their three-dimensional structure when: (1) the natural allergens were not available in sufficient amounts required for crystallography, (2) natural polymorphisms led to a lack of molecular homogeneity required for crystallization, (3) degradation or proteolytic cleavage of the natural allergen occurred, or (4) the natural allergens underwent post-translational modifications that impaired crystallization (i.e., glycosylation). Recombinant allergens can be engineered for high-level expression of homogeneous whole molecules or stable structural fragments, with mutations that prevent undesired N-glycosylation. They are usually expressed in vitro in the prokaryotic system Escherichia coli or in eukaryotic systems. Examples include yeasts such as Pichia pastoris or, less commonly, tobacco plants or Chinese hamster ovary cells [23, 24] . Allergens used for in vitro molecular diagnosis need to be properly folded and meet high standards of quality. Usually, mass spectrometry is used to confirm the amino acid sequence, and spectroscopic and/or NMR analysis are used to confirm the secondary and/or tertiary structures, respectively [25] [26] [27] [28] . A recent study applied high-throughput NMR technology to assess the molecular fold of food allergens utilized for diagnosis [29] . The structural conformation of an allergen preferentially recognized by IgE needs to be also taken into consideration for diagnostic purposes. Some allergens have regulatory functions resulting from major conformational changes upon calcium binding to EF-hand motifs. A recently determined solution structure of Phl p 7 showed three different conformations of the allergen [30] . Although most calcium-binding allergens have been described for pollens, they are also present in animals such as cockroach [31] . IgE antibody binding to the calcium-bound allergen is usually higher, suggesting that sensitization occurs preferably against that allergen form [31] . The allergen in the conformation that best binds IgE should be selected for diagnosis.
What We Learnt from Allergen Structures that Contributes to Diagnosis
Allergen Structure and Standardization
Currently, the potency of allergen extracts is determined as total allergenic activity, regardless of the allergen content, and is measured in units that differ among manufacturers. Allergen extracts contain a mix of allergenic and nonallergenic molecules and often include proteases that may reduce potency over time. Since 2001, the CREATE project funded by the European Union developed certified international standards with verifiable allergen content expressed in mass units [32, 33] . Nine recombinant major allergens from birch, timothy grass, olive pollen, and dust mite were measured by amino acid analysis, and their IgE reactivity was assessed by direct RAST, RAST inhibition, immunoblotting, and basophil histamine release. The recombinant allergens rBet v 1, rPhl p 5a, and rDer p 2 were found to be equivalent to the natural molecules in terms of structure and IgE antibody reactivity. As a follow-up project, rBet v 1 and Phl p 5a were selected and produced under GMP conditions for their establishment as European Pharmacopoeia (Ph. Eur.) Reference Standards through a project run by the Biological Standardisation Programme (BSP) of the European Directorate for the Quality of Medicines and HealthCare (EDQM) [34] . These standardization programs are made possible thanks to the availability of properly folded allergens whose molecular structure was tested by SDS-PAGE, mass spectrometry, circular dichroism spectroscopy, and small-angle X-ray scattering. Similar efforts will facilitate standardization of allergen extracts for diagnosis and immunotherapy, by using homogeneous preparations of properly folded allergen (natural or recombinant) with IgE reactivity comparable with the native counterpart. Recently, a single multi-allergen standard was prepared with eight natural allergens following the CREATE principles, for assessment of allergen exposure [35] . Such homogeneous solutions are easily obtained when molecules have a relatively stable structure. However, allergen degradation may occur due to the presence of proteolytic enzymes in extracts or the labile nature of certain allergenic molecules. The cockroach allergen Bla g 1 illustrates an example of a molecule that is difficult to standardize, because it naturally breaks down into fragments and has always been measured in arbitrary units. This allergen is formed by multiple consecutive amino acid repeats resulting from gene duplication of a~100 amino acid domain [36] . The basic structural unit of Bla g 1 was recently determined and facilitated standardization of assays in absolute units [37••] . This study showed that the structural integrity of either the whole allergen or a fragment is important for standardization. Finally, diagnostic products based on purified allergens should facilitate standardization and increase batch-to-batch consistency [38] .
Allergen Stability and Association with Disease
Allergenicity of food proteins has largely been associated with their lability, despite a lack of absolute correlation between digestibility measured in vitro and protein allergenicity [39] . Patients with oral allergy syndrome have IgE reactive to pepsin-sensitive allergens, whereas IgE from patients suffering systemic reactions recognize pepsin-resistant allergens. A study confirmed a difference in the lability of kiwi fruit allergens recognized by both kinds of patients [40] . A reduction in acidity reduced pepsin digestion and presumably increased the sensitizing capacity of the food. Interestingly, kiwi digestion resulted in the creation of new epitopes, either by aggregation, dissociation, or unmasking of allergenic protein digest products that were recognized by patients showing systemic reactions. The lability of some food allergens (i.e., Bet v 1-homologs from the Rosaceae family) is also the main reason why most commercial food extracts for SPTs (particularly those of the Rosaceae) are not reliable, and SPTs with fresh fruits and vegetables remain the best way to diagnose food allergy in vivo in these patients [41] . In contrast, lipid transfer proteins (LTP) are highly resistant to both heat treatment and proteolytic digestion. The stability of LTP has been associated with the induction of severe systemic reactions [42, 43] . These characteristics were attributed to the LTP three-dimensional structure composed of four α-helices, held by four disulfide bridges, with a large internal hydrophobic cavity that can harbor lipids. Similarly, digestion-resistant fragments of 2S albumins from cashew, Ana o 3, and peanut Ara h 6, retained IgEbinding epitopes, and disruption of disulfide bonds eliminated their IgE-binding capacity [44, 45•] . These studies highlight the protective effect of the three-dimensional structure of the allergen against digestion. Given the complexity of the human gastrointestinal tract, the use of physiologically relevant in vitro systems to evaluate digestibility of allergens has been evaluated [46] . These would involve not only the use of pepsin but also the simulation of the stomach and small intestine environment with addition of surfactants (i.e., phospholipids) and bile salts, considering the effect of food matrices on allergen digestion. In general, differences in molecular stability, which is determined by the three-dimensional structure of the allergen, can influence the variability in allergen composition of extracts used for diagnosis and immunotherapy. Also, conventional extracts may be deficient in significant IgEbinding components, due to differences in protein extractability [47] . These are factors to be considered for the production of diagnostic products.
Non-protein Molecules Involved in the Induction of Allergic Responses or IgE Recognition: Implications for Diagnosis
Carbohydrates N-glycans from plant and insect glycoproteins are common in allergens, and their IgE recognition in in vitro diagnostic tests may cause false-positive results. These sugars are known as cross-reactive carbohydrate determinants (CCD) and display a wide variety of structures that range from oligomannosidic type to complex Le(a)-carrying glycans [48, 49] . The most important CCD molecules are α1,3-fucose in insect glycoproteins or this fucose plus β1,2-xylose in plant glycoproteins [50, 51] . Two types of O-glycans have been identified in Art v1, and one of them, a mono-β-arabinosylated hydroxyproline, was found to constitute a new, potentially cross-reactive, carbohydrate determinant in plant proteins [52] .
The clinical relevance of carbohydrates as antigenic determinants has been a source of controversy for a long time. With some exceptions, cross-reactive carbohydrate determinants are mostly considered not to be clinically relevant. One third of the CCD-positive sera from patients with tomato allergy were reported to have biologically relevant CCD-specific IgE antibodies [53] . In this case, the use of natural allergens versus recombinant allergens expressed in prokaryotic systems would be preferred for diagnostic purposes. Conversely, the use of recombinant allergens expressed in E. coli, which are not glycosylated, would be preferred to allergens expressed in P. pastoris which may contain O-and Nlinked glycans that decrease the specificity of diagnostic tests [54] . Another option would be to express the allergen in P. pastoris with substitutions of specific sites involved in glycosylation. Recently, the use of a semisynthetic CCD blocker has been suggested to inhibit IgE binding to CCD and enhance diagnostic selectivity [55•] .
Lipids and Other Small Ligands An increasing number of allergens are known to bind lipids or small ligands. The identity of some allergen ligands was revealed in part thanks to determination of the three-dimensional structure of the allergen [37••] . The lipocalin allergen Bla g 4 binds tyramine and octopamine in solution, as shown by NMR and isothermal titration calorimetry [56] . Ara h 8 is a Bet v 1-like allergen that binds the isoflavones quercetin and apigenin, as well as resveratrol [57] . Some studies suggest that lipidic ligands from allergens could possess immunomodulatory properties. Der p 2 was reported to mimic the function of MD-2, the lipopolysaccharide (LPS)-binding component of the Toll-like receptor (TLR) 4 signaling complex, involved in activation of the innate immune system. This function was identified as a consequence of determining the immunoglobulin-like fold of Der p 2 [58] . Similarly, Fel d 1, Can f 6, and Par j 1 were proposed to bind LPS and had immunomodulatory activity [59, 60] . Bla g 1 is formed by capsules with an internal cavity that contains lipids, such as palmitic, oleic, and stearic acids. Lipidic ligands could also increase molecular stability, a desired quality for allergens to be used for diagnosis. The addition of phosphatidylcholine (which is a natural ligand of LTPs) to grape LTP contributed to the resistance of the protein to digestion [43] . The possible influence of allergen-associated lipids in diagnosis has not been investigated, as it has for carbohydrates.
Diagnosis and Molecular Determinants of Cross-Reactivity
The identification of cross-reactive allergens from different sources has improved the capacity to correctly diagnose and understand allergic reactions. The diagnostic procedure and therapeutic regimen can be simplified by selecting representative molecules out of clusters of cross-reactive allergens [61] . Species-specific allergens can be added to the panel for molecular diagnosis to contribute to the identification of the source of sensitization.
Clinical cross-reactivity indicates sensitization to crossreactive allergens (whereas the opposite is not always true). Therefore, an understanding of the molecular determinants of cross-reactivity is important for diagnostic purposes. In general, for cross-reactivity to occur, a high degree of amino acid identity throughout the entire protein is required (>70 %), whereas cross-reactivity is rare below 50 % identity [62] . The main determinant of cross-reactivity is the presence of identical amino acids at the molecular surface accessible to the antibodies.
Recently, unusual cases of cross-reactivity or lack thereof have been described that question the criterion to assess the allergenic risk of novel proteins according to the WHO/FAO/ EFSA/Codex [63] . This criterion is a value of 35 % or more amino acid identity over a sliding window of 80 amino acid residues. Despite a high sequence identity of 91 % between bovine and caprine β-caseins, there are cow's milk-tolerant patients that recognize the caprine allergen, without crossreacting with bovine β-casein [64] . Conversely, the kiwi allergen Act d 11 showed cross-reactivity with Bet v 1-like allergens, despite sharing low sequence identity (under 21 %) [65] . Recently, an unexpected IgE cross-reactivity, attributed to similar surface-exposed peptides, was found between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3, despite structural and sequence differences [66••] . This study is an exception to the general rule that cross-reactivity mainly occurs among homologous proteins that share similar structural features. Overall, these results demonstrate that the presence of conserved residues that define IgE antibody recognition of similar epitopes is responsible for IgE cross-reactivity. Therefore, criteria for prediction of allergenicity based on amino acid sequence homology are useful as guidelines, especially when dealing with new proteins of unknown structure, but they are not an accurate way to predict the presence of IgE antibody-binding epitopes and cross-reactivity.
Antigenic Structure for Diagnosis of Allergy and Design of Immunotherapy

Linear Epitopes: Markers of Severity or Persistence in Foods
Most studies for mapping IgE antibody-binding epitopes in allergens focus on the identification of linear epitopes. Synthetic peptides derived from the allergen amino acid sequence or allergen fragments are tested for IgE antibody binding in immunoblot or microarray assays, to identify linear IgE antibody-binding epitopes. This experimental approach has revealed interesting associations between IgE recognition patterns of linear epitopes and allergic disease, specifically for foods, including milk, peanut, egg, and lentil. Initial studies reported that the IgE recognition of at least one of three epitopes in caseins identified patients with persistence to milk allergy [67, 68] . The development of microarray technology allowed further exploration of the significance of linear epitopes in food allergens. Different IgE recognition patterns of sequential epitopes of four caseins and β-lactoglobulin were observed between reactive and tolerant milk-allergic patients [69] . Severity of cow's milk allergy was associated with a greater IgE epitope diversity (i.e., number of epitopes recognized) and higher IgE antibody affinity [70] . Regarding peanut, highly heterogeneous patient's IgE profiles to epitopes from Ara h 1, Ara h 2, and Ara h 3 were found, with no dominant epitopes in Ara h 2 [71, 72] . The clinical sensitivity to peanut allergens, determined by doubleblind, placebo-controlled peanut challenge, was positively related to the IgE (but not IgG4) epitope diversity. The epitope-recognition patterns remained stable over time, although no specific epitopes were associated with severe reactions to peanut [73] . Another study found a significantly greater IgE binding and broader epitope diversity in peanut-allergic patients compared with peanut-tolerant individuals, with no significant difference in IgG4 binding between groups [74••] . Regarding egg allergy, four linear epitopes from ovomucoid were identified as markers of persistent egg allergy [75] . A positive correlation between epitope diversity in the lentil allergen Len c 1, lentil-specific IgE levels, and respiratory symptoms was found [76] . These studies provided a detailed analysis of the IgE reactivity profiles of allergic patients to peptides (therefore linear epitopes) using microarray technology. However, the usefulness of this approach for clinical practice needs to be further evaluated [77] .
Conformational Epitopes for Diagnosis and Immunotherapy
Most epitopes in inhalant allergens are conformational, since these proteins do not undergo digestion and transformation processes typical of foods [78] . Increasing evidence shows that, in addition to linear epitopes, conformational epitopes are also important in food allergens if sensitization occurs to intact or partially digested allergens. Jarvinen et al. showed that persistent hen's egg allergy was associated with IgE recognition of not only linear but also conformational epitopes in ovomucoid and ovalbumin [75] . The IgE reactivity and allergenic potential of Pru p 3 was shown by using a reduced and alkylated form of recombinant Pru p 3 to depend mainly on conformational epitopes [79] . Another study proved that peptides identified as major linear epitopes on Pen a 1 and Ara h 2 had no relevant capacity to inhibit the IgE binding to the native allergen. Overall, these results reveal that conformational epitopes resulting from the three-dimensional structures of allergens need also to be considered to evaluate IgE responses to food allergens [80] .
Conformational epitopes are formed by amino acids that are brought close in space upon protein folding but are not necessarily contiguous in the sequence of the allergen. Most published evidence about the existence of conformational epitopes in allergens is indirect, derived from reduction of IgE antibody binding to modified allergens. These can be obtained by reduction of disulfide bonds that hold their three-dimensional structure, fragmentation or expression of recombinant fragments, or mutagenesis or alteration of allergen structure by calcium depletion [31, 44, 45•, 81] . The identification of the exact location of conformational epitopes has only been possible with the development of technologies that elucidate the three-dimensional structure of the proteins. Lysozyme was the first allergen to have antigenic determinants mapped by X-ray crystallography in the 1980s [82] . Since then, the structures of 11 allergen-antibody complexes have been determined. Two were complexes of Fab fragments of IgG antibodies with the birch pollen allergen Bet v 1 and the bee venom allergen Api m 2 (hyaluronidase) [83, 84] . The epitope in Bet v 1 was proven to be important for IgE antibody binding and for IgE cross-reactivity among homolog allergens [85] . Two complexes were formed using IgE antibody Fab obtained from combinatorial libraries from allergic patients. The allergens involved were β-lactoglobulin from bovine milk and timothy grass pollen allergen Phl p 2 [86, 87] . These studies were especially interesting given the fact that IgE is polyclonal, and native IgE is unavailable as a monoclonal antibody in large amounts required for X-ray crystallography. Thus, recombinant IgE represents the closest molecule representing a native antibody.
In recent years, an extensive analysis of antigenic determinants in cockroach and mite allergens has been performed following the determination of the crystal structures of antibody fragments in complex with Bla g 2, Der p 1, and Der f 1 (Table 1) (Fig. 1,  top) . The epitopes recognized by the IgG mAb were also involved in IgE antibody binding to Bla g 2 and group 1 mite allergens, as proven by detailed antibody binding analysis of allergen epitope mutants [90••, 91] . Structural analysis of these epitopes combined with site-directed mutagenesis and antibody-binding analysis revealed determinants of specificity and cross-reactivity for Der p 1 and Der f 1 (Fig. 1, bottom) .
Recently, the structures of isolated antibody constructs have also been solved. These include an antiBla g 1 IgG scFv, an anti-Bet v 1 IgE scFv and three anti-Der p 1 IgG Fab (mAb 4C1: 3RVT, 3RVU; mAb 10B9: 4POZ) [90••, 92, 93] . The use of antibodies specific for Blag 1 and Bet v 1 in mutant or peptidebinding experiments, respectively, led to the molecular location of species-specific epitopes. The identification of conformational epitopes involved in IgE antibody binding contributes to our understanding of antigenic relationships among molecules. This information is useful for diagnostic purposes, especially if dominant crossreactive epitopes are found among homologous allergens from different sources, as described for Bet v 1 and Der p 1 [85, 90••] . Most interestingly, the allergen structure and/or residues involved in IgE antibody binding can be specifically modified to produce hypoallergens for future use in immunotherapy. These low-IgE-binding molecules are expected to reduce side-effects due to increasing allergen doses administered during immunotherapy.
Conclusions
Correctly folded molecules are needed for diagnostic purposes, given the importance of the allergen fold as a determinant of allergenicity. The three-dimensional structure of allergens provides relevant information for diagnosis by facilitating structural and functional classification of allergens, allergen standardization, evaluation of the molecular stability of allergens for diagnostic products, and the analysis of proteinaceous and non-proteinaceous molecules that may influence diagnosis. In recent years, detailed analyses of the antigenic structure of allergens have led to the identification of common structural features and molecular determinants of specificity and cross-reactivity, including linear and conformational antibody binding epitopes relevant for allergic disease. Overall, this information is the basis for the design of molecules for diagnosis and immunotherapy. 
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